Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
August 30, 2023 16:15 ET
|
Alvotech
Product revenue for the first six months of 2023 increased to $22.7 million, compared to $3.9 million for the same period in 2022Investors, including Teva Pharmaceuticals, subscribed to Alvotech’s...
Alvotech mun birta uppgjör fyrri árshelmings 2023 þann 30. ágúst nk. og streyma uppgjörsfundi 31. ágúst nk. kl. 12:00 að íslenskum tíma
August 22, 2023 09:15 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) mun birta uppgjör fyrir fyrri helming ársins 2023 eftir lokun markaða í Bandaríkjunum, miðvikudaginn 30. ágúst 2023. Þá mun Alvotech halda kynningarfund fyrir fjárfesta í...
Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET
August 22, 2023 09:15 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...
BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023
August 02, 2023 07:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
Alvotech Completes $100 Million Convertible Bond Private Placement
July 31, 2023 04:00 ET
|
Alvotech
REYKJAVIK, Iceland, July 31, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02
June 28, 2023 19:00 ET
|
Alvotech
REYKJAVIK, Iceland, June 28, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech birtir upplýsingar um stöðu umsóknar um markaðsleyfi í Bandaríkjunum fyrir AVT02
June 28, 2023 19:00 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að Matvæla- og lyfjaeftirlit Bandaríkjanna (FDA) hefði sent svar við annarri umsókn félagsins um markaðsleyfi fyrir AVT02, sem jafnframt inniheldur gögn sem...
Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02
June 28, 2023 19:00 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the US Food and Drug...
BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives
June 27, 2023 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada
June 22, 2023 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...